Despite significant investment in drug discovery programs, research avenues pursued by industry and academia over the past three decades have largely failed to produce novel antibiotic agents because of knowledge gaps in basic science. For example, infections caused by Gram-negative bacilli present a pressing unmet need, as the cell structure of Gram-negative bacteria renders the pathogens particularly resistant to antibiotics.
As major pharmaceutical companies have downsized or abandoned antibiotic research and development, the task of addressing scientific obstacles has fallen to small companies and academic laboratories, whose resources may be limited. To rejuvenate antibiotic discovery, a growing number of experts agree that action is needed to address key scientific bottlenecks and to facilitate better collaboration across the private and public sectors.
America’s Overdose Crisis
Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care
From Lab Bench to Bedside: A Backgrounder on Drug Development
The process of creating new medicines is complex, time-consuming, and costly. Moving a potential therapy from concept to market can take between 10 and 15 years and cost developers as much as $1 billion.